Sociedad Americana de Hirudoterapia

Balancing Bleeding and Thrombosis in Dental Management of Patients on Novel Oral Anticoagulants: A Narrative Evidence Synthesis

Review published in Cureus (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosSeguridad y control de infeccionesChoudhary RS et al. · Cureus, 2025

Abstract

This narrative review explored the perioperative hemostatic challenges posed by novel oral anticoagulants (NOACs) in dental practice, synthesizing evidence on strategies to equilibrate bleeding and thrombotic risks during oral surgical interventions. A structured literature search across major databases, supplemented by manual searching of guidelines and conference proceedings from inception up to October 2025, prioritized high-quality trials, cohorts, and consensus documents while excluding isolated case reports. Pharmacokinetic variability among agents, such as rapid renal clearance of dabigatran versus mixed hepatic-biliary pathways for factor Xa inhibitors, guides precise timing of dose omission, with renal function emerging as a critical modifier. Risk stratification integrates thrombotic propensity via clinical scoring with procedural bleeding potential and classifies interventions from low (supragingival scaling) to high (extensive flap surgery). Evidence robustly supports uninterrupted anticoagulation for minor procedures when paired with local hemostatics; topical tranexamic acid, absorbable matrices, and primary closure effectively contain postoperative oozing. Moderate- to high-risk surgeries benefit from trough-timed interruptions, typically one skipped dose for twice-daily agents and two for once-daily, combined with minimally invasive techniques including flapless implantology, piezoelectric osteotomy, and laser coagulation. Reversal agents, including idarucizumab for dabigatran and andexanet alfa for apixaban, edoxaban, and rivaroxaban, remain emergency-only tools because of their logistical and prothrombotic constraints. Multidisciplinary preoperative consultation refines decisions in complex cases. Despite consistent observational safety signals, randomized dental-specific data are limited, bleeding definitions are heterogeneous, and the long-term thrombotic consequences of brief pauses are underexplored. Real-world confounders, such as renal decline, polypharmacy, and inflammation, are underrepresented. Nonetheless, this narrative review enables safe continuation in most scenarios, minimizing morbidity through pharmacokinetic awareness, local hemostatic rigor, and surgical conservatism. Future prospective registries with standardized outcomes are essential to validate interruption thresholds and adjunctive modalities in this expanding anticoagulation population.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Resumen

This narrative review explored the perioperative hemostatic challenges posed by novel oral anticoagulants (NOACs) in dental practice, synthesizing evidence on strategies to equilibrate bleeding and thrombotic risks during oral surgical interventions.

Por qué esto importa para la hirudoterapia

This narrative review synthesizes evidence on managing bleeding and thrombotic risks in dental patients taking novel oral anticoagulants, emphasizing pharmacokinetic timing, local hemostatics, and emergency reversal agents like idarucizumab and andexanet alfa. While bleeding management is a conceptual cornerstone of anticoagulant therapy, this article does not mention or involve leeches, hirudotherapy, or the leech secretome. The focus is strictly on the perioperative management of synthetic oral anticoagulants during oral surgical interventions. Consequently, it offers no direct relevance or practical clinical applicability to the core domains of the American Society of Hirudotherapy, serving only as general background on anticoagulant risks.

Citación

Balancing Bleeding and Thrombosis in Dental Management of Patients on Novel Oral Anticoagulants: A Narrative Evidence Synthesis

Choudhary RS et al. · Cureus, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.